EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug‐resistant epilepsy

Wenzheng Xiong iD, Tianrong Yeo, Jeanne Tan May May, Tor Demmers, Bryan Ceronie, Archana Ramesh, Ronan N McGinty, Sophia Michael, Emma Torzillo, Arjune Sen, Daniel C Anthony, Sarosh R Irani iD und 1 weitere

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Wenzheng Xiong und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Oxford, Oxford, UK. Hauptthemen laut MEDLINE: Drug Resistant Epilepsy, Encephalitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Medical Research Council, the Fulbright UK-US Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Differentiating forms of autoimmune encephalitis (AE) from other causes of seizures helps expedite immunotherapies in AE patients and informs studies regarding their contrasting pathophysiology. We aimed to investigate whether and how Nuclear Magnetic Resonance (NMR)‐based metabolomics could differentiate AE from drug‐resistant epilepsy (DRE), and stratify AE subtypes.

Methods

This study recruited 238 patients: 162 with DRE and 76 AE, including 27 with contactin‐associated protein‐like 2 (CASPR2), 29 with leucine‐rich glioma inactivated 1 (LGI1) and 20 with N‐methyl‐ d ‐aspartate receptor (NMDAR) antibodies. Plasma samples across the groups were analyzed using NMR spectroscopy and compared with multivariate statistical techniques, such as orthogonal partial least squares discriminant analysis (OPLS‐DA).

Results

The OPLS‐DA model successfully distinguished AE from DRE patients with a high predictive accuracy of 87.0 ± 3.1% (87.9 ± 3.4% sensitivity and 86.3 ± 3.6% specificity). Further, pairwise OPLS‐DA models were able to stratify the three AE subtypes. Plasma metabolomic signatures of AE included decreased high‐density lipoprotein (HDL, −(C H 2 ) n −, –C H 3 ), phosphatidylcholine and albumin (lysyl moiety). AE subtype‐specific metabolomic signatures were also observed, with increased lactate in CASPR2, increased lactate, glucose, and decreased unsaturated fatty acids (UFA, –C H 2 CH=) in LGI1, and increased glycoprotein A (GlycA) in NMDAR‐antibody patients.

Interpretation

This study presents the first non‐antibody‐based biomarker for differentiating DRE, AE and AE subtypes. These metabolomics signatures underscore the potential relevance of lipid metabolism and glucose regulation in these neurological disorders, offering a promising adjunct to facilitate the diagnosis and therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistant EpilepsyEncephalitisHumansFemaleMaleAdultMiddle AgedDiagnosis, DifferentialYoung AdultAutoantibodiesHashimoto DiseaseMetabolomicsNerve Tissue ProteinsAdolescentMembrane ProteinsMagnetic Resonance SpectroscopyIntracellular Signaling Peptides and ProteinsBiomarkersReceptors, N-Methyl-D-AspartateAutoimmune Diseases of the Nervous System

Substanzen

LGI1 protein, humanCNTNAP2 protein, humanAutoantibodiesNerve Tissue ProteinsMembrane ProteinsIntracellular Signaling Peptides and ProteinsBiomarkersReceptors, N-Methyl-D-Aspartate

Autor:innen und Institutionen

  • Department of Chemistry, University of Oxford, Oxford, UK.
  • Department of Pharmacology, Medical Sciences Division, University of Oxford, Oxford, UK.
  • Department of Neurology, National Neuroscience Institute, Singapore, Singapore.
  • Duke-NUS Medical School, Singapore, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.

ORCID-Profile: Wenzheng Xiong, Sarosh R Irani

Förderung

  • Medical Research Council
  • National Medical Research Council
  • the Fulbright UK-US Commission
  • Irish Clinical Academic Training Programme
  • British Medical Association
  • Epilepsy Research UK
  • UCB Pharma
  • Wellcome Trust Fellowship

Zitieren

APA

Xiong, W., Yeo, T., May, J. T. M., Demmers, T., Ceronie, B., Ramesh, A., McGinty, R. N., Michael, S., Torzillo, E., Sen, A., Anthony, D. C., Irani, S. R., & Probert, F. (2024). Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug‐resistant epilepsy. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52112

Vancouver

Xiong W, Yeo T, May JTM, Demmers T, Ceronie B, Ramesh A, et al. Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug‐resistant epilepsy. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52112

BibTeX
@article{Xiong2024,
  author = {Xiong, Wenzheng and Yeo, Tianrong and May, Jeanne Tan May and Demmers, Tor and Ceronie, Bryan and Ramesh, Archana and McGinty, Ronan N and Michael, Sophia and Torzillo, Emma and Sen, Arjune and Anthony, Daniel C and Irani, Sarosh R and Probert, Fay},
  title = {Distinct plasma metabolomic signatures differentiate autoimmune encephalitis from drug‐resistant epilepsy},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52112}
}
Kostenlos starten →